The stock of enGene Holdings Inc (ENGN) has seen a 53.72% increase in the past week, with a 45.05% gain in the past month, and a 17.30% flourish in the past quarter. The volatility ratio for the week is 8.00%, and the volatility levels for the past 30 days are at 13.63% for ENGN. The simple moving average for the last 20 days is 50.29% for ENGN stock, with a simple moving average of -0.40% for the last 200 days.
Is It Worth Investing in enGene Holdings Inc (NASDAQ: ENGN) Right Now?
Additionally, the 36-month beta value for ENGN is -0.67. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENGN is 16.22M and currently, short sellers hold a 3.07% ratio of that float. The average trading volume of ENGN on October 17, 2024 was 182.99K shares.
ENGN) stock’s latest price update
The stock price of enGene Holdings Inc (NASDAQ: ENGN) has surged by 22.90 when compared to previous closing price of 8.58, but the company has seen a 53.72% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-10-01 that BOSTON & MONTREAL–(BUSINESS WIRE)–enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of inducement equity awards to.
Analysts’ Opinion of ENGN
Many brokerage firms have already submitted their reports for ENGN stocks, with Oppenheimer repeating the rating for ENGN by listing it as a “Outperform.” The predicted price for ENGN in the upcoming period, according to Oppenheimer is $30 based on the research report published on August 28, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see ENGN reach a price target of $30. The rating they have provided for ENGN stocks is “Overweight” according to the report published on April 22nd, 2024.
Guggenheim gave a rating of “Buy” to ENGN, setting the target price at $34 in the report published on April 15th of the current year.
ENGN Trading at 57.75% from the 50-Day Moving Average
After a stumble in the market that brought ENGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.64% of loss for the given period.
Volatility was left at 13.63%, however, over the last 30 days, the volatility rate increased by 8.00%, as shares surge +38.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.68% upper at present.
During the last 5 trading sessions, ENGN rose by +44.17%, which changed the moving average for the period of 200-days by +7.97% in comparison to the 20-day moving average, which settled at $6.98. In addition, enGene Holdings Inc saw 14.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENGN starting from Cooper Ronald Harold Wilfred, who purchase 10,000 shares at the price of $5.70 back on Sep 27 ’24. After this action, Cooper Ronald Harold Wilfred now owns 10,000 shares of enGene Holdings Inc, valued at $57,000 using the latest closing price.
FONDS DE SOLIDARITE DES TRAVAI, the 10% Owner of enGene Holdings Inc, sale 47,854 shares at $15.00 during a trade that took place back on Apr 22 ’24, which means that FONDS DE SOLIDARITE DES TRAVAI is holding 3,036,153 shares at $717,810 based on the most recent closing price.
Stock Fundamentals for ENGN
The total capital return value is set at -0.22. Equity return is now at value -103.02, with -94.04 for asset returns.
Based on enGene Holdings Inc (ENGN), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -1.43. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -17.27.
Currently, EBITDA for the company is -25.89 million with net debt to EBITDA at 2.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.52.
Conclusion
In conclusion, enGene Holdings Inc (ENGN) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
